Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4902-4908

  Zaks, Tal Z ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FREUND ADJUVANT;

ADENOCARCINOMA; ARTICLE; BREAST METASTASIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY METASTASIS; PHENOTYPE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CELL LINE; EPITOPES; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

EID: 0032213456     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Rosenberg, S. A. Principles of cancer management: biologic therapy. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer, pp. 349-374. Philadelphia: Lippincott-Raven, 1997.
2. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., and Francke, U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
3. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.), 319: 226-230, 1986.
4. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
5. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992.
6. Katsumata, M., Okudaira, T., Samanta, A., Clark, D. P., Drebin, J. A., Jolicoeur, P., and Greene, M. I. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat. Med., 1: 644-648, 1995.
7. Schlegel, J., Trenkle, T., Stumm, G., and Kiessling, M. Growth inhibition by dominant-negative mutations of the neu-encoded oncoprotein. Int. J. Cancer, 70: 78-83, 1997.
8. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., and Livingston, R. B. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
9. Fisk, B., Hudson, J. M., Kavanagh, J., Wharton, J. T., Murray, J. L., Ioannides, C. G., and Kudelka, A. P. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res., 17: 45-53, 1997.
10. Fisk, B., Chesak, B., Pollack, M. S., Wharton, J. T., and Ioannides, C. G. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol., 157: 415-427, 1994.
11. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
12. Kono, K., Halapi, E., Hising, C., Petersson, M., Gerdin, E., Vanky, F., and Kiessling, R. Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. Int. J. Cancer, 70: 112-119, 1997.
13. Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M. L., Cheever, M. A., and Sherman, L. A. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum. Immunol., 52: 109-118, 1997.
14. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
15. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res., 54: 1071-1076, 1994.
16. Pierce, L. J., Merino, M. J., D'Angelo, T., Barker, E. A., Gilbert, L., Cowan, K. H., Steinberg, S. M., and Glatstein, E. Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer? Int. J. Radiat. Oncol. Biol. Phys., 28: 395-403, 1994.
17. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1993.
18. Salter, R. D., and Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J., 5: 943-949, 1986.
19. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., and Appella, E. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
20. Riddell, S. R., and Greenberg, P. D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods, 128: 189-201, 1990.
21. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
22. Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H. G., Kanz, L., and Brugger, W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res., 58: 732-736, 1998.
23. Kawakami, Y., and Rosenberg, S. A. T-cell recognition of self peptides as tumor rejection antigens. Immunol. Res., 15: 179-190, 1996.
24. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
25. Dadmarz, R. D., Ordoubadi, A., Mixon, A., Thompson, C. O., Barracchini, K. C., Hijazi, Y. M., Steller, M. A., Rosenberg, S. A., and Schwartzentruber, D. J. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J. Sci. Am., 2: 263-272, 1996.
26. Nagata, Y., Furagen, R., Hiasa, A., Ikeda, H., Ohta, N., Furukawa, K., Nakamura, H., Kanematsu, T., and Shiku, H. Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol., 159: 1336-1343, 1997.
27. Peoples, G. E., Yoshino, I., Douville, C. C., Andrews, J. V., Goedegebuure, P. S., and Eberlein, T. J. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J. Immunol., 152: 4993-4999, 1994.
28. Papewalis, J., Nikitin, A. Y., and Rajewsky, M. F. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res., 19: 5452-5452, 1991.
29. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am., 3: 37-44, 1997.
30. Salgaller, M. L., Marincola, F. M., Cormier, J. N., and Rosenberg, S. A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res., 56: 4749-4757, 1996.
31. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol., 59: 1-14, 1998.
32. Toes, R. E. M., Offringa, R., Blom, R. J. J., Melief, C. J. M., and Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA, 93: 7855-7860, 1996.
33. Schild, H., Rotzschke, O., Kalbacher, H., and Rammensee, H. G. Limit of T cell tolerance to self proteins by peptide presentation. Science (Washington DC), 247: 1587-1589, 1990.
34. Xue, B. H., Zhang, Y., Sosman, I. A., and Peace, D. J. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate. 30: 73-78, 1997.
35. Abrams, S. I., Stanziale, S. F., Lunin, S. D., Zaremba, S., and Schlom, J. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur. J. Immunol., 26: 435-443, 1996.
36. Gjertsen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Solheim, B. G., Soreide, O., Thorsby, E., and Gaudernack, G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet, 346: 1399-1400, 1995.
37. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. E., Wharton, J. T., and O'Brian, C. A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol., 151: 225-234, 1993.
38. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Parikh, A. S., DiMaio, J. M., Lyerly, H. K., Gazdar, A. F., and Eberlein, T. J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res., 54: 3387-3390, 1994.
39. Peiper, M., Goedegebuure, P. S., Linehan, D. C., Ganguly, E., Douville, C. C., and Eberlein, T. J. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytoloxic T lymphocytes. Eur. J. Immunol., 27: 1115-1123, 1997.